Cefiderocol is primarily used in the treatment of serious bacterial infections, particularly those caused by multidrug-resistant Gram-negative bacteria. It is effective against pathogens such as Pseudomonas aeruginosa, Acinetobacter baumannii, and Enterobacteriaceae, which are often resistant to other antibiotics. This makes it a critical option for treating complicated urinary tract infections, hospital-acquired pneumonia, and ventilator-associated pneumonia. Its unique mechanism of action, which involves utilizing the bacteria's own iron transport system to penetrate the cell wall, enhances its efficacy against resistant strains. It is typically administered intravenously in hospital settings for patients with limited treatment options due to antibiotic resistance.